Versant Venture Capital VI, L.P. - Significant Ownership

Signature - Title
/s/Max Eisenberg - Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the GP of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P.
Location
San Francisco, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Versant Venture Capital VI, L.P..

Significant Ownership of Versant Venture Capital VI, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.1% $24.7M 3.33M Versant Venture Capital VI, L.P. Nov 10, 2025
TPST Tempest Therapeutics, Inc. Common Stock, par value $0.001 per share 3.7% $1.11M -$13.3M 163K -92.3% Versant Vantage II, L.P. Aug 11, 2025
LENZ LENZ Therapeutics, Inc. Common Stock, par value $0.00001 per share 3.4% $48.9M -$6.19M 1.05M -11.2% Versant Venture Capital VI, L.P. Nov 5, 2025
LVTX LAVA Therapeutics N.V. Common Shares, par value Euro 0.12 per share 0% $0 -$3.63M 0 -100% Versant Venture Capital VI, L.P. Sep 19, 2025

Schedules 13D/G Reported by Versant Venture Capital VI, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.